Studies have confirmed that PD-1 monoclonal antibody can help improve and regulate cellular immune function, play a role in tumor killing, inhibit disease progression, and obtain satisfactory clinical benefits. However, the total effective rate was lower than that reported in the literature (64%, 70%), which may be related to the fact that all the patients involved in the study were advanced patients.<br>
正在翻译中..